Urolithin B

Urolithin B is the terminal gut-microbiota metabolite of dietary ellagitannins — produced downstream of ellagic acid by colonic bacteria after pomegranate, walnut, or berry intake. Among the urolithin family, UroB occupies a unique position: it is the only congener with a peer-reviewed in vivo hypertrophy result and a granted patent specifically for muscle growth. Its mechanism converges on two of the most heavily trafficked anabolic nodes in skeletal muscle — the androgen receptor and mTORC1 — while simultaneously suppressing the ubiquitin-proteasome atrogenes that drive muscle wasting.

Androgen Receptor Agonism#

UroB binds and activates the androgen receptor (AR) in skeletal muscle, and this engagement is non-redundant — without functional AR signalling, the hypertrophic effect collapses entirely. In C2C12 myotubes, both genetic AR knockdown and pharmacological AR blockade with flutamide abolished UroB-induced increases in myotube diameter and protein synthesis. The patent literature describes the mechanism in explicit terms.

"The present invention relates to the use of urolithin B as androgen receptor agonist to increase muscle mass and treat or prevent muscle disorders." — Francaux M, Rodriguez J, et al., US Patent Application US20160045472A1 (2016)

Practically, this places UroB in the conceptual neighbourhood of a very weak, non-suppressive SARM-like signal — AR engagement in muscle tissue without the exogenous-androgen burden on the HPG axis. The community-relevant translation is a modest training-response amplifier in the AR-mediated hypertrophy lane, with no shutdown and no PCT obligation.

mTORC1 Activation and Protein Synthesis#

Downstream of AR engagement, UroB drives phosphorylation of S6K1 and 4E-BP1 — the two canonical mTORC1 substrates that gate ribosomal protein synthesis. Puromycin-incorporation assays confirmed that the upstream signalling translates into actual translation, with treated myotubes synthesising new protein at meaningfully higher rates. Rapamycin pre-treatment abolished the effect, confirming mTORC1 dependence.

"Urolithin B enhanced muscle hypertrophy in vitro and in vivo through an androgen receptor-dependent mechanism and mTORC1 activation, while also inhibiting muscle atrophy gene expression." — Rodriguez et al., Journal of Cachexia, Sarcopenia and Muscle (2017)

This is the same final-common-pathway every serious hypertrophy stimulus eventually routes through — leucine, mechanical tension, insulin, IGF-1, AAS. UroB just enters the pathway from an unusual angle (a polyphenol metabolite engaging AR), which is what makes the result novel rather than redundant.

Atrogene Suppression and Anti-Catabolic Effect#

The other half of net muscle accretion is proteolysis suppression, and UroB delivers on this lane independently of its synthesis-driving effects. Treated muscle shows downregulation of MuRF1 and atrogin-1 (MAFbx) — the two E3 ubiquitin ligases responsible for tagging contractile proteins for proteasomal destruction during fasting, denervation, immobilisation, glucocorticoid exposure, and aggressive caloric deficit. In the denervation-atrophy mouse model, continuous UroB infusion meaningfully attenuated the muscle loss that follows sciatic nerve section.

The use-case translation is direct: UroB is mechanistically positioned to protect lean mass during cuts, contest prep, injury layoffs, and any phase where the catabolic environment is winning. This is the cleanest published rationale for keeping it in a stack during aggressive deficits rather than only during accumulation blocks.

Aromatase Inhibition#

Beyond muscle, UroB exhibits aromatase (CYP19A1) inhibition, blocking the conversion of testosterone to estradiol at the enzyme level. The activity is documented in the Sigma-Aldrich monograph and is consistent with broader polyphenol-class endocrine modulation.

"Urolithin B is described as a selective androgen receptor modulator that stimulates skeletal muscle growth and inhibits aromatase activity in vitro." — Sigma-Aldrich, Urolithin B (SML1649) product monograph (2024)

This is a soft, supplement-tier inhibition — not a replacement for anastrozole, letrozole, or exemestane when aromatisable AAS are in play at supraphysiologic doses. The practical implications are twofold: first, UroB's effect will stack additively with a true AI, which means AI titration on a UroB-containing protocol should be driven by sensitive-assay estradiol bloodwork rather than copy-pasted from prior cycles; second, in natural or TRT-base contexts, the mild aromatase brake plus the AR engagement creates a modest androgen-leaning shift in the testosterone:estradiol ratio without exogenous androgen exposure.

Sustained Exposure via Glucuronide Conjugates#

Pharmacokinetically, the active picture is shaped by phase II metabolism. UroB is rapidly glucuronidated in the gut wall and liver, and the glucuronide conjugate is the dominant circulating species. Critically, the conjugate is not a dead-end metabolite — it functions as a long-lived reservoir with a substantially longer half-life than the aglycone, and tissue β-glucuronidases can locally regenerate free UroB at sites of inflammation and active turnover.

"Urolithin B-glucuronide was found in plasma samples after pomegranate juice consumption and remained detectable in urine up to 48 hours, indicating extended systemic exposure." — Seeram et al., The Journal of Nutrition (2006)

The practical consequence is that once-daily oral dosing is mechanistically defensible despite the modest aglycone half-life — the conjugate pool flattens the trough, steady-state is reached within 3–5 days of daily administration, and pulsing or peri-workout timing offers no obvious advantage over consistent daily intake with a fat-containing meal.

Common (most users)#

• Mild GI upset — nausea or loose stool show up occasionally at oral doses ≥500mg, consistent with the broader urolithin class. Administer with a fat-containing meal (which also improves absorption of this lipophilic aglycone), and split AM/PM if a single 500–1000mg bolus is the trigger.
• Transient bloating — the hygroscopic powder and variable capsule excipients can drive low-grade GI discomfort in the first 1–2 weeks. Usually self-limiting; switching to a third-party HPLC-verified capsule format typically resolves it.
• No subjective stimulation or sedation — UroB is silent on energy, mood, and sleep. Users expecting a "felt" effect on day one are reading the wrong compound; the readout is in training quality, recovery, and bloodwork over 8–16 weeks.

Uncommon (dose-dependent or individual)#

• Estradiol suppression on stack — UroB inhibits aromatase (Sigma-Aldrich SML1649), and that activity stacks additively with anastrozole, letrozole, or exemestane. In protocols where an AI was already dialled in on a prior cycle, adding 500–1000mg/day UroB can over-crash E2. Pull a sensitive estradiol assay at the 4–6 week mark and titrate the AI down, not the UroB.
• Joint dryness / low-E2 symptoms — the downstream consequence of the above. Dry joints, flat libido, and low mood on a UroB-containing protocol point at E2, not at UroB itself. Bloodwork resolves the question.
• Lipid drift — not clearly documented for UroB specifically, but worth checking on long (≥12 week) runs given the AR-agonist mechanism. A standard lipid panel at the 12-week mark covers it.
• Inter-individual response variability — the urolithin metabotype literature suggests ~10–40% of the population are efficient endogenous producers, and the rest are not. Direct oral UroB bypasses the conversion bottleneck, but downstream conjugation and tissue distribution still vary substantially. If a 12-week 500mg/day protocol produces nothing measurable, dose response is logarithmic — pushing to 1g/day rarely rescues a non-responder.

Rare but serious#

• No serious adverse events documented in any preclinical UroB work or in the class-level human urolithin A data, where 1000mg/day for four months produced only mild/moderate, unrelated adverse events (Hodzic Kuerec et al. 2024).
• Theoretical hormone-sensitive tissue stimulation — UroB's AR agonism plus context-dependent ER activity means any new breast lump, prostate symptom change, or unexplained vaginal bleeding warrants stopping the compound and a workup. Direction of effect matters more than magnitude here.
• Hepatic strain on heavy polypharmacy — UroB is glucuronidated heavily; in protocols already loading the UGT pathway (high-dose orals, certain statins, valproate), monitor ALT/AST quarterly.

Hard contraindications#

• Active or treated hormone-sensitive malignancy (breast, prostate, endometrial). AR agonism and context-dependent ER activity are both the wrong direction.
• Concurrent therapeutic anti-androgen therapy — bicalutamide, enzalutamide, systemic flutamide. UroB's AR agonism is mechanistically opposed; flutamide abolished UroB hypertrophy in vitro (Rodriguez et al. 2017), and the converse — UroB blunting a prescribed anti-androgen — is the relevant clinical concern.
• Pregnancy and lactation. No data. Do not run.
• Stacking with an aromatase inhibitor without bloodwork. Additive AI activity is real. AI dosing on a UroB-containing protocol is titrated from a sensitive E2 assay, not from prior-cycle assumptions.

Gender and PCT considerations#

UroB does not suppress the HPG axis. No PCT is required, and it is not an AAS regardless of the AR-agonist mechanism — the agonism is mild, tissue-biased toward skeletal muscle, and the dose-exposure profile is orders of magnitude below an exogenous androgen.

Female users: virilization risk at supplement-tier doses (50–1000mg/day) is effectively nil. The more relevant consideration is the aromatase-inhibitory activity, which can disrupt hormone-replacement regimens or stack unfavourably with a prescribed AI. Female subjects on HRT should pull an E2 panel at 6–8 weeks and adjust the HRT side of the equation. Avoid entirely during pregnancy and lactation.

Male users on AAS: the on-cycle aromatase inhibition is weak, polyphenol-grade, and not a substitute for anastrozole or exemestane when running aromatizable compounds at supraphysiologic doses. Treat it as a soft modulator that adds to the AI stack — not as a replacement layer.

Male users on a hair stack (finasteride/dutasteride at standard 1mg/0.5mg doses): the mechanistic conflict is real on paper but the clinical magnitude appears small at typical UroB doses. No published interaction data exist either way; users running both should monitor scalp response over the 12-week mark and treat any visible regression as a signal to drop one.